Jump to content
 







Main menu
   


Navigation  



Main page
Contents
Current events
Random article
About Wikipedia
Contact us
Donate
 




Contribute  



Help
Learn to edit
Community portal
Recent changes
Upload file
 








Search  

































Create account

Log in
 









Create account
 Log in
 




Pages for logged out editors learn more  



Contributions
Talk
 



















Contents

   



(Top)
 


1 References  














NE-100







Add links
 









Article
Talk
 

















Read
Edit
View history
 








Tools
   


Actions  



Read
Edit
View history
 




General  



What links here
Related changes
Upload file
Special pages
Permanent link
Page information
Cite this page
Get shortened URL
Download QR code
Wikidata item
 




Print/export  



Download as PDF
Printable version
 
















Appearance
   

 






From Wikipedia, the free encyclopedia
 


NE-100
Identifiers
  • 4-Methoxy-3-(2-phenylethoxy)-N,N-dipropylbenzeneethanamine

CAS Number
PubChem CID
IUPHAR/BPS
ChemSpider
UNII
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC23H33NO2
Molar mass355.522 g·mol−1
3D model (JSmol)
  • CCCN(CCC)CCC1=CC(=C(C=C1)OC)OCCC2=CC=CC=C2

  • InChI=1S/C23H33NO2/c1-4-15-24(16-5-2)17-13-21-11-12-22(25-3)23(19-21)26-18-14-20-9-7-6-8-10-20/h6-12,19H,4-5,13-18H2,1-3H3

  • Key:YBLIQJGXRLZBCZ-UHFFFAOYSA-N

NE-100or4-methoxy-3-(2-phenylethoxy)-N,N-dipropylbenzeneethanamine is a selective sigma-1 receptor antagonist, with a reported binding affinityofKi = 1.03 ± 0.01 nM, and more than 205 times selectivity over the sigma-2 receptor.[1][2]

NE-100 was one of the earliest selective sigma-1 receptor ligands reported and has been widely used as a pharmacological tool. The original, eight step synthesis of NE-100 was reported by Atsuro Nakazato and colleagues of Taisho Pharmaceutical Company in 1999.[3] More recently, Michael Kassiou and co-workers have reported a more expedient synthesis of NE-100 that proceeds in 56% unoptimized yield over 4 steps.[4]

References[edit]

  1. ^ Okuyama S, Nakazato A (1999). "NE-100: A novel sigma receptor antagonist". CNS Drug Rev. 2 (2): 226–237. doi:10.1111/j.1527-3458.1996.tb00299.x.
  • ^ Berardi F, Ferorelli S, Colabufo NA, Leopoldo M, Perrone R, Tortorella V (2001). "A multireceptorial binding reinvestigation on an extended class of sigma ligands: N-[omega-(indan-1-yl and tetralin-1-yl)alkyl] derivatives of 3,3-dimethylpiperidine reveal high affinities towards sigma1 and EBP sites". Bioorg. Med. Chem. 9 (5): 1325–35. doi:10.1016/s0968-0896(01)00011-6. PMID 11377189.
  • ^ Nakazato A, Ohta K, Sekiguchi Y, Okuyama S, Chaki S, Kawashima Y, Hatayama K (1999). "Design, Synthesis, Structure-Activity Relationships, and Biological Characterization of Novel Arylalkoxyphenylalkylamine s Ligands as Potential Antipsychotic Drugs". Journal of Medicinal Chemistry. 42 (6): 1076–1087. doi:10.1021/jm980212v. PMID 10090790.
  • ^ Banister SD, Moussa IA, Jorgensen WT, Chua SW, Kassiou M (2011). "Molecular hybridization of 4-azahexacyclo[5.4.1.02,6.03,10.05,9.08,11]dodecane-3-ol with sigma (s) receptor ligands modulates off-target activity and subtype selectivity". Bioorg. Med. Chem. Lett. 21 (12): 3622–3626. doi:10.1016/j.bmcl.2011.04.098. PMID 21555222.

  • Retrieved from "https://en.wikipedia.org/w/index.php?title=NE-100&oldid=1136249231"

    Category: 
    Phenol ethers
    Hidden categories: 
    Articles with short description
    Short description matches Wikidata
    Articles without EBI source
    Chemical pages without DrugBank identifier
    Articles without KEGG source
    Drugs missing an ATC code
    Drugs with no legal status
    Articles containing unverified chemical infoboxes
     



    This page was last edited on 29 January 2023, at 12:58 (UTC).

    Text is available under the Creative Commons Attribution-ShareAlike License 4.0; additional terms may apply. By using this site, you agree to the Terms of Use and Privacy Policy. Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc., a non-profit organization.



    Privacy policy

    About Wikipedia

    Disclaimers

    Contact Wikipedia

    Code of Conduct

    Developers

    Statistics

    Cookie statement

    Mobile view



    Wikimedia Foundation
    Powered by MediaWiki